RxDoctor Payments Data

Athena Papas

General Practice · Boston, MANPI 1164431573

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $6,918 of the $6,967 with a category attached, or 99.3%. Otsuka Pharmaceutical Development & Commercialization, Inc. accounts for 81.7% of it on its own, with 1 other manufacturer making up the rest. Among general practice clinicians in MA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$6,967in general payments, 2019–2025

Across 5 payments — averaging $1393.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka Pharmaceutical Development & Commercialization, Inc.$6K
  • Biogen$1K
$1,382,524in research payments, 2019–2025

Across 63 payments — averaging $21,945 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Novartis$931K
  • Amgen$388K
  • Otsuka Pharmaceutical Development & Commercialization, Inc.$20K
  • Biogen$17K
  • Solventum Corporation$14K
  • Gilead$11K
  • plus $672 from 1 others

What the payments were for

  • Consulting fees$6,91899%
  • Food & beverage$491%

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$6,967 in reported general payments places this provider in the 95th percentile of 2,391 general practice providers in Massachusetts.

See all general practice providers in Massachusetts →

Other general practice in Boston

See the full list for Massachusetts →

Where these figures come from

Is this you, or does something look wrong? →